Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787613 | 0.76 | HDAC2 (0.43) | SMN1; SMN2TSHR | |
| SCHEMBL7787176 | 0.74 | ALDH1A1 (0.61) | TSHR | |
| SCHEMBL7795694 | 0.72 | MMP3 (0.51) | SMN1; SMN2MMP1MMP3 | |
| SCHEMBL8669614 | 0.70 | PPARG (0.52) | — | |
| SCHEMBL16039660 | 0.70 | CARM1 (0.47) | SMN1; SMN2SIGMAR1TMEM97 | |
| SCHEMBL10993880 | 0.69 | CARM1 (0.44) | SMN1; SMN2SIGMAR1TSHR | |
| SCHEMBL40675 | 0.69 | KDM4A (0.66) | LTA4HSMN1; SMN2SIGMAR1TMEM97 | |
| SCHEMBL7270813 | 0.69 | CARM1 (0.50) | SMN1; SMN2SIGMAR1TMEM97 | |
| SCHEMBL8662550 | 0.68 | PPARG (0.50) | — | |
| Hydrochloric Acid SCHEMBL21043700 | 0.68 | SMN1; SMN2 (0.51) | SMN1; SMN2SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | ANTXR2, HAAO, PAOX | MMP13 448/4885LTA4H 1624/4885SMN1; SMN2 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.